Am I missing something?4 Feb 2026 16:21
The latest RNS has increased volume significantly but, although the share price has improved, it is still well below the year's high. Looking at the high volume of sales it's obvious that many traders are selling and taking their profits which is normal. However, this RNS has finally convinced me that Avacta is a near certainty to be winner so I can't understand why big biotech funds and investment trusts haven't started to add this company to their portfolios. If they had the price would have increased much more.